Evonik wins CPHI award: Evonik stock sits 3.66 percent below 52-week high

Published on 10/21/2026 at 10:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Self Driving Labs runs 100 experiments daily. Evonik stock costs EUR 21.04 on October 21, 2026, 0.48 percent above its Xetra close.

Technology award and dates

On October 7, 2026, Evonik won the CPHI Pharma Award for Digital Transformation.
Evonik's 2025 sales were EUR 14.1 billion and adjusted EBITDA was EUR 1.9 billion.
Evonik stock trades at EUR 21.04 at 10:43 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.48 percent above the Xetra close of October 20, 2026 at EUR 20.94.
Evonik's next quarterly report is scheduled for November 3, 2026.

Isometrische 3D-Illustration der Spezialchemie-Wertschöpfungskette von Rohstoff bis globale Distribution — Evonik Industries DE000EVNK013 als isometrisches 3D-Diagramm der Spezialchemie-Wertschöpfungskette von Rohstoff bis Vertrieb, Illustration mit AI erstellt.

Evonik stock (ISIN DE000EVNK013) was trading at EUR 21.04 at Lang & Schwarz on October 21, 2026, at 10:43 a.m. CEST, 0.48 percent above the Xetra close. The company won the CPHI Pharma Award for its Self Driving Labs on October 7, 2026, according to Evonik.

Automation adds a growth angle

The award recognizes a digital platform that combines artificial intelligence, automation and chemical expertise for pharmaceutical process development. Evonik said industrial use cases have reached up to 100 autonomous experiments per day, giving the Health Care business a concrete technology marker rather than only a broad innovation narrative.

The same release said Evonik generated sales of EUR 14.1 billion and adjusted EBITDA of EUR 1.9 billion in fiscal year 2025. Those figures provide the scale against which the newer laboratory activity must be judged, while the award itself does not change the group's reported earnings.

Three dates define the recent sequence

On September 25, 2026, Evonik confirmed receipt of a non-binding approach from BASF for a potential takeover, while the outcome remained open, according to BASF. On October 5, 2026, Berenberg raised its rating from Sell to Hold and lifted its target from EUR 15.50 to EUR 20.00, as reported by Boerse Express.

On October 7, 2026, Evonik's Self Driving Labs won the CPHI Pharma Award for Digital Transformation, with the platform reporting up to 100 autonomous experiments per day, according to Evonik.

What dates matter next?

Evonik's investor-relations calendar schedules the third-quarter 2026 report for November 3, 2026 and the fourth-quarter 2026 report for March 4, 2027, according to Evonik. The November publication is the next dated test of whether the operating recovery can support the valuation shaped by takeover speculation.

Stock remains below the yearly high

At EUR 21.04, Evonik's market capitalization was EUR 9.8 billion on October 21, 2026, and the stock sat 3.66 percent below its 52-week high of EUR 21.84. The 52-week range ran from EUR 12.49 to EUR 21.84, leaving the award as an operating signal while investors wait for the next reported figures.

Evonik stock was trading at EUR 21.04 at Lang & Schwarz on October 21, 2026, at 10:43 a.m. CEST, 0.48 percent above the Xetra close of October 20, 2026 at EUR 20.94. The further course of trading is shown by the continuously updated real-time quote of Evonik stock.